KR20220140532A - 이식 부정맥의 치료 및 예방 방법 - Google Patents

이식 부정맥의 치료 및 예방 방법 Download PDF

Info

Publication number
KR20220140532A
KR20220140532A KR1020227029054A KR20227029054A KR20220140532A KR 20220140532 A KR20220140532 A KR 20220140532A KR 1020227029054 A KR1020227029054 A KR 1020227029054A KR 20227029054 A KR20227029054 A KR 20227029054A KR 20220140532 A KR20220140532 A KR 20220140532A
Authority
KR
South Korea
Prior art keywords
administration
amiodarone
ivabradine
cardiomyocytes
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227029054A
Other languages
English (en)
Korean (ko)
Inventor
비욘 크놀만
로버트 스콧 티에스
윌리엄 롭 맥랠란
겐타 나카무라
찰스 이. 머리
Original Assignee
유니버시티 오브 워싱톤
벤더르빌트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 워싱톤, 벤더르빌트 유니버시티 filed Critical 유니버시티 오브 워싱톤
Publication of KR20220140532A publication Critical patent/KR20220140532A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227029054A 2020-02-10 2021-02-09 이식 부정맥의 치료 및 예방 방법 Withdrawn KR20220140532A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
US62/972,330 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (1)

Publication Number Publication Date
KR20220140532A true KR20220140532A (ko) 2022-10-18

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227029054A Withdrawn KR20220140532A (ko) 2020-02-10 2021-02-09 이식 부정맥의 치료 및 예방 방법

Country Status (11)

Country Link
US (1) US20230077983A1 (enExample)
EP (1) EP4103206A4 (enExample)
JP (1) JP2023512843A (enExample)
KR (1) KR20220140532A (enExample)
CN (1) CN115484966A (enExample)
AU (1) AU2021218653A1 (enExample)
BR (1) BR112022015768A2 (enExample)
CA (1) CA3166678A1 (enExample)
IL (1) IL295236A (enExample)
MX (1) MX2022009807A (enExample)
WO (1) WO2021163037A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245409A1 (en) * 2019-06-06 2020-12-10 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
US20250101382A1 (en) * 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2024073499A2 (en) * 2022-09-28 2024-04-04 Bluerock Therapeutics Lp Compositions and methods for treating graft-related arrhythmia
WO2025137525A1 (en) * 2023-12-22 2025-06-26 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192305A1 (en) * 2012-01-20 2013-08-30 Singapore Health Serv Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof in screening for agents
EP2833930B1 (en) * 2012-04-04 2018-05-30 University of Washington through its Center for Commercialization Systems and method for engineering muscle tissue
US9855317B2 (en) * 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
JP7333271B2 (ja) * 2017-03-15 2023-08-24 ユニヴァーシティ オブ ワシントン 心筋細胞の成熟および生着を増強するための方法および組成物
WO2020245409A1 (en) * 2019-06-06 2020-12-10 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof

Also Published As

Publication number Publication date
EP4103206A1 (en) 2022-12-21
CN115484966A (zh) 2022-12-16
JP2023512843A (ja) 2023-03-29
MX2022009807A (es) 2022-11-10
AU2021218653A1 (en) 2022-09-01
BR112022015768A2 (pt) 2022-11-22
US20230077983A1 (en) 2023-03-16
EP4103206A4 (en) 2024-03-13
IL295236A (en) 2022-10-01
CA3166678A1 (en) 2021-08-19
WO2021163037A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
US20230077983A1 (en) Methods of treating and preventing engraftment arrhythmias
US10568912B2 (en) Treatment of heart disease
JP7333271B2 (ja) 心筋細胞の成熟および生着を増強するための方法および組成物
JP7091427B2 (ja) 心不全の治療方法
Houshmand et al. Role of atrial natriuretic Peptide in oxytocin induced cardioprotection
BR112013004700B1 (pt) uso de células precursoras de células-tronco mesenquimais (msc) cd271+
US20060263338A1 (en) Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts
US8889122B2 (en) Cellular cardiomyoplasty as supportive therapy in patients with heart disease
Schoenfeld et al. The existence of myocardial repair: mechanistic insights and enhancements
Wang et al. Reconstitute the damaged heart via the dual reparative roles of pericardial adipose-derived flk-1+ stem cells
US20230250393A1 (en) Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
Akar et al. Failing heart; remodel, replace or repair?/Terminal dönem kalp yetersizligi: Kalp nakli mi? Yeniden biçimlendirme mi? Yoksa onarim mi?
CN121586768A (zh) 心肌细胞群、药物组合物、制备心肌细胞群的方法和心肌细胞球体
Winter From cardiogenesis to cardiac regeneration: focus on epicardium-deri ed cells
Nakamura et al. Article Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes
García Analysis of the regenerative potential of the induced pluripotent stem cells in a model of acute myocardial infarction in mice
du Pré Circadian Rhythms in Cardiovascular Disease. From Bench to Bedside
Agnoletti et al. Percutaneous coronary injection of bone marrow cells in small experimental animals: Small is not too small
Rodrigo Intramyocardial bone marrow cell injection for ischemic heart disease: efficacy
Wolfram et al. Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000